Measurement of B cell maturation antigen-Directed CAR T Cells During TAK-573 Study Participation
Not Recruiting
1-99 years
Male
Phase
N/A
10 participants needed
1 Location
Brief description of study
The primary objective of this pilot study is to explore in a preliminary fashion whether
administration of TAK-573 increases the number of BCMA-specific T cells in blood samples
from patients with myeloma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Multiple myeloma
-
Age: Between 1 Years - 99 Years
-
Gender: Male
Male or Femal Multiple myeloma
Updated on
17 Dec 2021.
Study ID: 844868
